Ophiuchus Technologies ^None

Ophiuchus Technologies AG is a Swiss regenerative medicine company that produces and distributes a new cell therapy called DrSC\xae Neural. The company was founded in 2013 as a spin-out company of the NOVAGENESIS FOUNDATION. The technology behind DrSC\xae Neural was developed over a decade of research in the USA and Canada. The therapy is designed to treat patients with spinal cord injury, traumatic brain injury, primary progressive MS, and ALS/motor neurone disease. DrSC\xae Neural is the first and only engineered autologous neural stem cell product for personalized cell replacement of damaged neuronal tissue.